Cargando…

The Mechanism of Action of the Histone Deacetylase Inhibitor Vorinostat Involves Interaction with the Insulin-Like Growth Factor Signaling Pathway

A correlation between components of the insulin-like growth factor (IGF) system and endometrial cancer risk has been shown in recent studies. The antitumor action of vorinostat, a histone deacetylase inhibitor, involves changes in the expression of specific genes via acetylation of histones and tran...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sarfstein, Rive, Bruchim, Ilan, Fishman, Ami, Werner, Haim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169604/ https://www.ncbi.nlm.nih.gov/pubmed/21931726 http://dx.doi.org/10.1371/journal.pone.0024468

Ejemplares similares

Insulin-like Growth Factor 1 Signaling Axis Meets p53 Genome Protection Pathways
por: Werner, Haim, et al.
Publicado: (2016)

Metformin Downregulates the Insulin/IGF-I Signaling Pathway and Inhibits Different Uterine Serous Carcinoma (USC) Cells Proliferation and Migration in p53-Dependent or -Independent Manners
por: Sarfstein, Rive, et al.
Publicado: (2013)

The IGF Hormonal Network in Endometrial Cancer: Functions, Regulation, and Targeting Approaches
por: Bruchim, Ilan, et al.
Publicado: (2014)

Genome-Wide Analyses Identify Filamin-A As a Novel Downstream Target for Insulin and IGF1 Action
por: Aizen, Daniel, et al.
Publicado: (2018)

Nuclear insulin-like growth factor-1 receptor (IGF1R) displays proliferative and regulatory activities in non-malignant cells
por: Solomon-Zemler, Ravid, et al.
Publicado: (2017)

Identification of Insulin-Like Growth Factor-I Receptor (IGF-IR) Gene Promoter-Binding Proteins in Estrogen Receptor (ER)-Positive and ER-Depleted Breast Cancer Cells
por: Sarfstein, Rive, et al.
Publicado: (2010)

Werner et al. Identification of Insulin-Like Growth Factor-I Receptor (IGF-IR) Gene Promoter-Binding Proteins in Estrogen Receptor (ER)-Positive and ER-Depleted Breast Cancer Cells
por: Sarfstein, Rive, et al.
Publicado: (2010)

Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo
por: Hrzenjak, Andelko, et al.
Publicado: (2010)

Tumor suppressor p53 regulates insulin receptor (INSR) gene expression via direct binding to the INSR promoter
por: Sarfstein, Rive, et al.
Publicado: (2020)

The Role of Nuclear Insulin and IGF1 Receptors in Metabolism and Cancer
por: Werner, Haim, et al.
Publicado: (2021)

Effect of histone deacetylase inhibitor (vorinostat) on new-onset diabetes induced by tacrolimus
por: Bakhdar, Fatmah A., et al.
Publicado: (2022)

Oncogenic fusion proteins adopt the insulin-like growth factor signaling pathway
por: Werner, Haim, et al.
Publicado: (2018)

Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor
por: Richon, V M
Publicado: (2006)

Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma
por: Saelen, Marie Grøn, et al.
Publicado: (2012)

Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells
por: Eto, Shotaro, et al.
Publicado: (2019)

Identification of ZYG11A as a candidate IGF1-dependent proto-oncogene in endometrial cancer
por: Achlaug, Laris, et al.
Publicado: (2019)

Insulin receptor compensates for IGF1R inhibition and directly induces mitogenic activity in prostate cancer cells
por: Weinstein, Doron, et al.
Publicado: (2014)

Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells
por: Phillip, Cornel J, et al.
Publicado: (2012)

Improved Anticancer Activities of a New Pentafluorothio-Substituted Vorinostat-Type Histone Deacetylase Inhibitor
por: Goehringer, Nils, et al.
Publicado: (2021)

Differential Effects of Insulin and IGF1 Receptors on ERK and AKT Subcellular Distribution in Breast Cancer Cells
por: Sarfstein, Rive, et al.
Publicado: (2019)

Identification of UDP-Glucuronosyltransferase 2B15 (UGT2B15) as a Target for IGF1 and Insulin Action
por: Sarfstein, Rive, et al.
Publicado: (2022)

Crafting Carbazole-Based Vorinostat and Tubastatin-A-like Histone Deacetylase (HDAC) Inhibitors with Potent in Vitro and in Vivo Neuroactive Functions
por: Reddy, R. Gajendra, et al.
Publicado: (2019)

Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma
por: O'Connor, O A
Publicado: (2006)

ZYG11A Is Expressed in Epithelial Ovarian Cancer and Correlates With Low Grade Disease
por: Achlaug, Laris, et al.
Publicado: (2021)

The Histone Deacetylase Inhibitor, Vorinostat, Represses Hypoxia Inducible Factor 1 Alpha Expression through Translational Inhibition
por: Hutt, Darren M., et al.
Publicado: (2014)

Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis
por: Laengle, Johannes, et al.
Publicado: (2020)

Histone Deacetylase Inhibitors Romidepsin and Vorinostat Promote Hepatitis B Virus Replication by Inducing Cell Cycle Arrest
por: Yang, Yang, et al.
Publicado: (2021)

Systems Analysis of Insulin and IGF1 Receptors Networks in Breast Cancer Cells Identifies Commonalities and Divergences in Expression Patterns
por: Sarfstein, Rive, et al.
Publicado: (2020)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat
por: Maxwell, Jill W., et al.
Publicado: (2020)

Brief Report: Case Comparison of Therapy With the Histone Deacetylase Inhibitor Vorinostat in a Neonatal Calf Model of Pulmonary Hypertension
por: Applegate, Tanya J., et al.
Publicado: (2021)

Histone deacetylases inhibition by SAHA/Vorinostat normalizes the glioma microenvironment via xCT equilibration
por: Wolf, Ines M. L., et al.
Publicado: (2014)

Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia
por: Okabe, Seiichi, et al.
Publicado: (2014)

Laron Syndrome Research Paves the Way for New Insights in Oncological Investigation
por: Werner, Haim, et al.
Publicado: (2020)

Long-Term IGF1 Stimulation Leads to Cellular Senescence via Functional Interaction with the Thioredoxin-Interacting Protein, TXNIP
por: Nagaraj, Karthik, et al.
Publicado: (2022)

Essential role of insulin-like growth factor 2 in resistance to histone deacetylase inhibitors
por: Lee, Su-Chan, et al.
Publicado: (2016)

DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines
por: LaBonte, Melissa J, et al.
Publicado: (2009)

Synergistic silencing of α-globin and induction of γ-globin by histone deacetylase inhibitor, vorinostat as a potential therapy for β-thalassaemia
por: Mettananda, Sachith, et al.
Publicado: (2019)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
por: Munster, P N, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_hcefq7g9562thqu6926i20atr7